{"transactions":[{"id":12474,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN OF THE BOARD AND CEO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T18:12:11.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":36523,"price":232.08,"value":8476257.84,"ownership":{"direct":true},"balance_after":178737,"source":{"system":"sec-edgar","filing":"0001699914-26-000004","document":"form4-03032026_110308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000004/form4-03032026_110308.xml","form_type":"4"}},{"id":13236,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":81251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,084 on February 18, 2027, 27,084 on February 18, 2028, and 27,083 on February 18, 2029."}],"balance_after":81251,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":81251},"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13235,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":22124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":215260,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13234,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":14452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":193136,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13233,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":12030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":178684,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13232,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":33833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":166654,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":26183,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-03-04T17:00:18.000Z","date":"2025-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":27186,"price":205.02,"value":5573673.72,"ownership":{"direct":true},"balance_after":132821,"source":{"system":"sec-edgar","filing":"0001415889-25-006583","document":"form4-03042025_050314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588925006583/form4-03042025_050314.xml","form_type":"4"}},{"id":28036,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2025-02-18T17:00:10.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":83333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,778 on February 13, 2026, 27,778 on February 13, 2027, and 27,777 on February 13, 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,778 on February 13, 2026, 27,778 on February 13, 2027, and 27,777 on February 13, 2028."}],"balance_after":83333,"derivative":{"exercise_price":192.86,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":83333},"source":{"system":"sec-edgar","filing":"0001415889-25-004456","document":"form4-02182025_050203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588925004456/form4-02182025_050203.xml","form_type":"4"}},{"id":28035,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T17:00:10.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":14454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":160007,"source":{"system":"sec-edgar","filing":"0001415889-25-004456","document":"form4-02182025_050203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588925004456/form4-02182025_050203.xml","form_type":"4"}},{"id":28034,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T17:00:10.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":12030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":145553,"source":{"system":"sec-edgar","filing":"0001415889-25-004456","document":"form4-02182025_050203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588925004456/form4-02182025_050203.xml","form_type":"4"}},{"id":28033,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T17:00:10.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":10146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":133523,"source":{"system":"sec-edgar","filing":"0001415889-25-004456","document":"form4-02182025_050203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588925004456/form4-02182025_050203.xml","form_type":"4"}},{"id":28032,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T17:00:10.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":24732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":123377,"source":{"system":"sec-edgar","filing":"0001415889-25-004456","document":"form4-02182025_050203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588925004456/form4-02182025_050203.xml","form_type":"4"}},{"id":44460,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2024-03-01T17:50:42.000Z","date":"2024-02-29","kind":"exercise","planned":false,"acquired":false,"shares":10140,"price":54.86,"value":556280.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":54.86,"exercise_date":"2017-02-18","expiration_date":"2026-02-17","underlying":"Common Stock","underlying_shares":10140},"source":{"system":"sec-edgar","filing":"0001415889-24-006163","document":"form4-03012024_050320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924006163/form4-03012024_050320.xml","form_type":"4"}},{"id":44459,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2024-03-01T17:50:42.000Z","date":"2024-02-29","kind":"exercise","planned":false,"acquired":false,"shares":11420,"price":61.36,"value":700731.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":61.36,"exercise_date":"2018-02-16","expiration_date":"2027-02-15","underlying":"Common Stock","underlying_shares":11420},"source":{"system":"sec-edgar","filing":"0001415889-24-006163","document":"form4-03012024_050320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924006163/form4-03012024_050320.xml","form_type":"4"}},{"id":44458,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T17:50:42.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":47319,"price":176.46,"value":8349910.74,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $176.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":98645,"source":{"system":"sec-edgar","filing":"0001415889-24-006163","document":"form4-03012024_050320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924006163/form4-03012024_050320.xml","form_type":"4"}},{"id":44457,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T17:50:42.000Z","date":"2024-02-29","kind":"sale","planned":false,"acquired":false,"shares":21560,"price":176.44,"value":3804046.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.39 to $176.57, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":145964,"source":{"system":"sec-edgar","filing":"0001415889-24-006163","document":"form4-03012024_050320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924006163/form4-03012024_050320.xml","form_type":"4"}},{"id":44456,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T17:50:42.000Z","date":"2024-02-29","kind":"exercise","planned":false,"acquired":true,"shares":10140,"price":54.86,"value":556280.4,"ownership":{"direct":true},"balance_after":167524,"source":{"system":"sec-edgar","filing":"0001415889-24-006163","document":"form4-03012024_050320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924006163/form4-03012024_050320.xml","form_type":"4"}},{"id":44455,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T17:50:42.000Z","date":"2024-02-29","kind":"exercise","planned":false,"acquired":true,"shares":11420,"price":61.36,"value":700731.2,"ownership":{"direct":true},"balance_after":157384,"source":{"system":"sec-edgar","filing":"0001415889-24-006163","document":"form4-03012024_050320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924006163/form4-03012024_050320.xml","form_type":"4"}},{"id":44454,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T17:50:42.000Z","date":"2024-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":37638,"price":178.99,"value":6736825.62,"ownership":{"direct":true},"balance_after":145964,"source":{"system":"sec-edgar","filing":"0001415889-24-006163","document":"form4-03012024_050320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924006163/form4-03012024_050320.xml","form_type":"4"}},{"id":45452,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2024-02-20T17:15:14.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":59888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,963 on February 15, 2025, 19,963 on February 15, 2026, and 19,962 on February 15, 2027."}],"balance_after":59888,"derivative":{"exercise_price":0,"exercise_date":"2025-02-15","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":59888},"source":{"system":"sec-edgar","filing":"0001415889-24-004416","document":"form4-02202024_050205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924004416/form4-02202024_050205.xml","form_type":"4"}},{"id":45451,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T17:15:14.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":12030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":183602,"source":{"system":"sec-edgar","filing":"0001415889-24-004416","document":"form4-02202024_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924004416/form4-02202024_050205.xml","form_type":"4"}},{"id":45450,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T17:15:14.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":10146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":171572,"source":{"system":"sec-edgar","filing":"0001415889-24-004416","document":"form4-02202024_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924004416/form4-02202024_050205.xml","form_type":"4"}},{"id":45449,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T17:15:14.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":13216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":161426,"source":{"system":"sec-edgar","filing":"0001415889-24-004416","document":"form4-02202024_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924004416/form4-02202024_050205.xml","form_type":"4"}},{"id":45448,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES & CHIEF OPERATING OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T17:15:14.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":49565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":148210,"source":{"system":"sec-edgar","filing":"0001415889-24-004416","document":"form4-02202024_050205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588924004416/form4-02202024_050205.xml","form_type":"4"}},{"id":57884,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VICE CHAIRMAN"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T16:30:28.000Z","date":"2023-02-28","kind":"tax_withholding","acquired":false,"shares":48335,"price":154.28,"value":7457123.8,"ownership":{"direct":true},"balance_after":98645,"source":{"system":"sec-edgar","filing":"0001415889-23-003821","document":"form4-03022023_040309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588923003821/form4-03022023_040309.xml","form_type":"4"}},{"id":58502,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VICE CHAIRMAN"}}],"security":"Option (Right to Buy)","published_at":"2023-02-21T17:59:24.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":45577,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,193 on February 16, 2024, 15,192 on February 16, 2025, and 15,192 on February 16, 2026."}],"balance_after":45577,"derivative":{"exercise_price":149.62,"exercise_date":"2024-02-16","expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":45577},"source":{"system":"sec-edgar","filing":"0001415889-23-002935","document":"form4-02212023_100213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588923002935/form4-02212023_100213.xml","form_type":"4"}},{"id":58501,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VICE CHAIRMAN"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T17:59:24.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":10148,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":146980,"source":{"system":"sec-edgar","filing":"0001415889-23-002935","document":"form4-02212023_100213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588923002935/form4-02212023_100213.xml","form_type":"4"}},{"id":58500,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VICE CHAIRMAN"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T17:59:24.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":13218,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":136832,"source":{"system":"sec-edgar","filing":"0001415889-23-002935","document":"form4-02212023_100213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588923002935/form4-02212023_100213.xml","form_type":"4"}},{"id":58499,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VICE CHAIRMAN"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T17:59:24.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":16220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":123614,"source":{"system":"sec-edgar","filing":"0001415889-23-002935","document":"form4-02212023_100213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588923002935/form4-02212023_100213.xml","form_type":"4"}},{"id":58498,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VICE CHAIRMAN"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T17:59:24.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":69517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":107394,"source":{"system":"sec-edgar","filing":"0001415889-23-002935","document":"form4-02212023_100213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000141588923002935/form4-02212023_100213.xml","form_type":"4"}},{"id":69872,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-01T18:07:15.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":4236,"price":149.0633,"value":631432.1388,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.87 to $149.44 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":37877,"source":{"system":"sec-edgar","filing":"0001179110-22-001828","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001828/edgar.xml","form_type":"4"}},{"id":69871,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-01T18:07:15.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":26937,"price":148.4901,"value":3999877.8237,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.87 to $148.86 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42113,"source":{"system":"sec-edgar","filing":"0001179110-22-001828","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001828/edgar.xml","form_type":"4"}},{"id":69870,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-01T18:07:15.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":11932,"price":147.4134,"value":1758936.6888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.875 to $147.86 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":69050,"source":{"system":"sec-edgar","filing":"0001179110-22-001828","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001828/edgar.xml","form_type":"4"}},{"id":69869,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-01T18:07:15.000Z","date":"2022-02-25","kind":"tax_withholding","acquired":false,"shares":34286,"price":149.54,"value":5127128.44,"ownership":{"direct":true},"balance_after":80982,"source":{"system":"sec-edgar","filing":"0001179110-22-001828","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001828/edgar.xml","form_type":"4"}},{"id":70234,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Option (Right to Buy)","published_at":"2022-02-22T17:39:59.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":48161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,054 on February 17, 2023, 16,054 on February 17, 2024, and 16,053 on February 17, 2025."}],"balance_after":48161,"derivative":{"exercise_price":144.54,"exercise_date":"2023-02-17","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":48161},"source":{"system":"sec-edgar","filing":"0001179110-22-001515","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001515/edgar.xml","form_type":"4"}},{"id":70233,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T17:39:59.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":11565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were release d on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":115268,"source":{"system":"sec-edgar","filing":"0001179110-22-001515","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001515/edgar.xml","form_type":"4"}},{"id":70232,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T17:39:59.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":16220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":103703,"source":{"system":"sec-edgar","filing":"0001179110-22-001515","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001515/edgar.xml","form_type":"4"}},{"id":70231,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T17:39:59.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":8857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":87483,"source":{"system":"sec-edgar","filing":"0001179110-22-001515","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001515/edgar.xml","form_type":"4"}},{"id":70230,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T17:39:59.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":40749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":78626,"source":{"system":"sec-edgar","filing":"0001179110-22-001515","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911022001515/edgar.xml","form_type":"4"}},{"id":92082,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-03-02T20:32:31.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":14006,"price":107.74,"value":1509006.44,"ownership":{"direct":true},"balance_after":37877,"source":{"system":"sec-edgar","filing":"0001179110-21-002608","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911021002608/edgar.xml","form_type":"4"}},{"id":92731,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Option(right to buy)","published_at":"2021-02-22T18:25:02.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":65217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,739 on February 18, 2022, 21,739 on February 18, 2023, and 21,739 on February 18, 2024."}],"balance_after":65217,"derivative":{"exercise_price":105.92,"exercise_date":"2022-02-18","expiration_date":"2031-02-17","underlying":"Common Stock","underlying_shares":65217},"source":{"system":"sec-edgar","filing":"0001179110-21-002052","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911021002052/edgar.xml","form_type":"4"}},{"id":92730,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T18:25:02.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":16220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":51883,"source":{"system":"sec-edgar","filing":"0001179110-21-002052","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911021002052/edgar.xml","form_type":"4"}},{"id":92729,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T18:25:02.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":8859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":35663,"source":{"system":"sec-edgar","filing":"0001179110-21-002052","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911021002052/edgar.xml","form_type":"4"}},{"id":92728,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T18:25:02.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":1485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":26804,"source":{"system":"sec-edgar","filing":"0001179110-21-002052","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911021002052/edgar.xml","form_type":"4"}},{"id":92727,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T18:25:02.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":5049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":25319,"source":{"system":"sec-edgar","filing":"0001179110-21-002052","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911021002052/edgar.xml","form_type":"4"}},{"id":106572,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-03T16:54:59.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":7438,"price":85.42,"value":635353.96,"ownership":{"direct":true},"balance_after":20270,"source":{"system":"sec-edgar","filing":"0001179110-20-002857","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911020002857/edgar.xml","form_type":"4"}},{"id":107155,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Option (right to buy)","published_at":"2020-02-24T18:01:46.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":106382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 35,461 on February 20, 2021, 35,461 on February 20, 2022, and 35,460 on February 20, 2023."}],"balance_after":106382,"derivative":{"exercise_price":93.5,"exercise_date":"2021-02-20","expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":106382},"source":{"system":"sec-edgar","filing":"0001179110-20-002133","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911020002133/edgar.xml","form_type":"4"}},{"id":107154,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T18:01:46.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":8859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":27708,"source":{"system":"sec-edgar","filing":"0001179110-20-002133","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911020002133/edgar.xml","form_type":"4"}},{"id":107153,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T18:01:46.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":1485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":18849,"source":{"system":"sec-edgar","filing":"0001179110-20-002133","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911020002133/edgar.xml","form_type":"4"}},{"id":107152,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T18:01:46.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":1710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":17364,"source":{"system":"sec-edgar","filing":"0001179110-20-002133","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911020002133/edgar.xml","form_type":"4"}},{"id":107151,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T18:01:46.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":4741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":15654,"source":{"system":"sec-edgar","filing":"0001179110-20-002133","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911020002133/edgar.xml","form_type":"4"}},{"id":118969,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common stock, $0.01 par value","published_at":"2019-03-04T16:56:48.000Z","date":"2019-02-28","kind":"tax_withholding","acquired":false,"shares":3206,"price":79.41,"value":254588.46,"ownership":{"direct":true},"balance_after":10913,"source":{"system":"sec-edgar","filing":"0001179110-19-003084","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911019003084/edgar.xml","form_type":"4"}},{"id":119500,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Option (Right to buy)","published_at":"2019-02-22T17:18:25.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":54517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,173 on February 21, 2020, 18,172 on February 21, 2021, and 18,172 on February 21, 2022."}],"balance_after":54517,"derivative":{"exercise_price":79.02,"exercise_date":"2020-02-21","expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":54517},"source":{"system":"sec-edgar","filing":"0001179110-19-002364","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911019002364/edgar.xml","form_type":"4"}},{"id":119499,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T17:18:25.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":1485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":14119,"source":{"system":"sec-edgar","filing":"0001179110-19-002364","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911019002364/edgar.xml","form_type":"4"}},{"id":119498,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T17:18:25.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":1710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":12634,"source":{"system":"sec-edgar","filing":"0001179110-19-002364","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911019002364/edgar.xml","form_type":"4"}},{"id":119497,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T17:18:25.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":1695,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":10924,"source":{"system":"sec-edgar","filing":"0001179110-19-002364","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911019002364/edgar.xml","form_type":"4"}},{"id":119496,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T17:18:25.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":2353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":9229,"source":{"system":"sec-edgar","filing":"0001179110-19-002364","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911019002364/edgar.xml","form_type":"4"}},{"id":131341,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T17:31:34.000Z","date":"2018-02-28","kind":"sale","acquired":false,"shares":4294,"price":119.4349,"value":512853.4606,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.40 to $119.501, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6876,"source":{"system":"sec-edgar","filing":"0001179110-18-003340","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018003340/edgar.xml","form_type":"4"}},{"id":131340,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T17:31:34.000Z","date":"2018-02-28","kind":"tax_withholding","acquired":false,"shares":2387,"price":118.26,"value":282286.62,"ownership":{"direct":true},"balance_after":11170,"source":{"system":"sec-edgar","filing":"0001179110-18-003340","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018003340/edgar.xml","form_type":"4"}},{"id":131939,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-20T18:08:39.000Z","date":"2018-02-20","kind":"sale","acquired":false,"shares":592,"price":120.33,"value":71235.36,"ownership":{"direct":true},"balance_after":13557,"source":{"system":"sec-edgar","filing":"0001179110-18-002429","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018002429/edgar.xml","form_type":"4"}},{"id":131938,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-20T18:08:39.000Z","date":"2018-02-20","kind":"sale","acquired":false,"shares":400,"price":120.2901,"value":48116.04,"ownership":{"direct":true},"balance_after":14149,"source":{"system":"sec-edgar","filing":"0001179110-18-002429","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018002429/edgar.xml","form_type":"4"}},{"id":131937,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-20T18:08:39.000Z","date":"2018-02-19","kind":"tax_withholding","acquired":false,"shares":838,"price":118.6,"value":99386.8,"ownership":{"direct":true},"balance_after":14549,"source":{"system":"sec-edgar","filing":"0001179110-18-002429","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018002429/edgar.xml","form_type":"4"}},{"id":132306,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Option (right to buy)","published_at":"2018-02-16T17:56:43.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":8030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 2,677 on February 15, 2019, 2,676 on February 15, 2020, and 2,677 on February 15, 2021."}],"balance_after":8030,"derivative":{"exercise_price":114.36,"exercise_date":"2019-02-15","expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":8030},"source":{"system":"sec-edgar","filing":"0001179110-18-002301","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018002301/edgar.xml","form_type":"4"}},{"id":132305,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T17:56:43.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":1710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":15387,"source":{"system":"sec-edgar","filing":"0001179110-18-002301","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018002301/edgar.xml","form_type":"4"}},{"id":132304,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T17:56:43.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":1975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":13677,"source":{"system":"sec-edgar","filing":"0001179110-18-002301","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018002301/edgar.xml","form_type":"4"}},{"id":132303,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T17:56:43.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":1695,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":11702,"source":{"system":"sec-edgar","filing":"0001179110-18-002301","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911018002301/edgar.xml","form_type":"4"}},{"id":136841,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2017-09-29T17:02:30.000Z","date":"2017-09-28","kind":"sale","acquired":false,"shares":6699,"price":88,"value":589512.0,"ownership":{"direct":true},"balance_after":10007,"source":{"system":"sec-edgar","filing":"0001179110-17-012766","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911017012766/edgar.xml","form_type":"4"}},{"id":142233,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2017-03-10T17:22:29.000Z","date":"2017-03-10","kind":"sale","acquired":false,"shares":5132,"price":65.29,"value":335068.28,"ownership":{"direct":true},"balance_after":16706,"source":{"system":"sec-edgar","filing":"0001179110-17-004442","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000117911017004442/edgar.xml","form_type":"4"}}]}